Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 6/20 | 0.33 |
| ▸ | TNKS | O95271 | 4/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133551 | 0.86 | MGLL (0.33) | MGLLFLT4 | |
| SCHEMBL16006664 | 0.77 | PARP1 (0.45) | PARP1TNKSTNKS2FLT4 | |
| SCHEMBL16135656 | 0.73 | KDR (0.40) | PARP1FLT4 | |
| SCHEMBL20430124 | 0.70 | MAP3K14 (0.33) | FLT4ASIC3 | |
| SCHEMBL16157874 | 0.67 | FLT4 (0.33) | FLT4 | |
| SCHEMBL20430083 | 0.65 | ASIC3 (0.31) | FLT4ASIC3 | |
| SCHEMBL16154662 | 0.65 | PARP1 (0.40) | PARP1TNKSTNKS2FLT4KDM4E | |
| SCHEMBL11269556 | 0.65 | ASIC3 (0.44) | FLT4KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16135661 | 0.63 | CLK4 (0.44) | — | |
| SCHEMBL2919116 | 0.62 | CHEK1 (0.53) | PARP1TNKSTNKS2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | MGLL 2769/4885PARP1 2578/4885TNKS 3587/4885 |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | MGLL 2861/4885PARP1 2482/4885TNKS 3459/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | MGLL 2769/4885PARP1 2578/4885TNKS 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.